Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZY19489 + Ferroquine in Asymptomatic Malaria
NCT05911828Phase 1Recruiting
- Sponsor
- Zydus Lifesciences Limited
- Start
- Aug 2024
- Primary completion
- Feb 2025
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Plasmodium falciparum malaria comparing ZY19489 + Ferroquine with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Aug 2024; status: recruiting.
02
Drugs
ZY19489ferroquine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT05911828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911828.